| Collaboration of Two HCV Pharmaceuticals |
 |
 |
 |
|
Thursday, 24 February 2011 15:19
|
|
It was announced on January 10th, 2011 that Bristol-Myers Squibb (BMS) and Pharmasset will collaborate on a new study that will test BMS’s HCV NS5A inhibitor BMS-790052 and Pharmasset’s HCV polymerase inhibitor PSI - 7977 with and without ribavirin to treat HCV. This collaboration is a tremendous move forward for the development of more medications to treat hepatitis C. Collaborations between pharmaceutical companies to explore different various combinations of drugs has been encouraged by the FDA and many HCV advocates. This is a win-win situation for everyone – it will speed up the testing of various combinations of medications that will eventually lead to better treatment options for people with chronic hepatitis C. Hopefully, other pharmaceuticals will take notice and begin to dialogue and work together to develop other combination drug regimes to treat HCV. Source: BMS & Pharmasset Press Release http://www.hcvadvocate.org Add this page to your favourite Social Bookmarking websites;         
  |
